Edit |   |
---|---|
Antigenic Specificity | CD3E/MS4A1 (Plamotamab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 kappa / scFv-h-CH2-CH3 |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Plamotamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/MS4A1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Plamotamab (XmAb13676) is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on plamotamab. CD20 is highly expressed on B-cell tumor cells, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) cells. Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing tumor cells. The structural stability and modularity enabled by the XmAb Bispecific Fc domain allowed the tuning of plamotamab's potency to balance anti-tumor activity with the reduction of immune toxicity that can result from T-cell activation. |
Immunogen | n/a |
Other Names | Plamotamab, CD3E/MS4A1, 2138442-31-4 |
Gene, Accession # | CAS: 2138442-31-4 |
Catalog # | abx831522 |
Price | please inquire |
Order / More Info | CD3E/MS4A1 (Plamotamab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950